Prostate Cancer Metastatic
📧 Sign up to get email alerts when something new happens for Prostate Cancer Metastatic.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-24Clinical Trial Results: A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer [Phase 1, Phase 2]
A phase 1/2 trial evaluating talazoparib in combination with temozolomide in prostate cancer has been terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2022-12-20Clinical Trial Update: The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer [Phase 2]
Phase 2 clinical trial assessing 68Ga-PSMA-11 to enhance diagnosis of primary and metastatic prostate cancer; study completed with results p…
-
CLINICAL_TRIALS trial_result · 2022-11-03Clinical Trial Update: Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL) [Phase 2]
Phase 2 trial update evaluating maintenance olaparib in metastatic prostate cancer with partial or stable response after docetaxel.
-
CLINICAL_TRIALS trial_result · 2021-03-02Clinical Trial Update: The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients [Phase 4]
Phase 4 trial update investigating lipid reprogramming with rosuvastatin in castrated Egyptian patients with metastatic prostate cancer.
-
CLINICAL_TRIALS trial_result · 2018-10-09Clinical Trial Update: Selective Treatment According to Molecular Subtype of Prostate Cancer [Phase 2]
A Phase 2 clinical trial update exploring selective treatment based on molecular subtype in prostate cancer, including castration-resistant …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-06-12Clinical Trial Update: Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer [Phase 2]
Phase 2 trial comparing concurrent versus sequential sipuleucel-T and abiraterone in metastatic castration-resistant prostate cancer has com…